Supervisory Board

Dr. PetitBon is Senior Advisor to BlackRock. He was general partner and co-founder of private debt provider Kreos Capital where he focused on healthcare investments until BlackRock acquired Kreos Capital. Prior to co-founding Kreos, Maurizio held senior positions in consulting at PMA Europe in London and Milano and at SRI International, in Menlo Park, California and London where he advised a number of U.S., European and Japanese technology companies and Private Equity funds on business development and M&A strategies. He also held a number of managerial positions at Emerson Electric, Digital Equipment and Xerox. Dr. PetitBon holds a doctor’s degree in mechanical engineering from the University of Rome and an MBA from INSEAD in Fontainebleau, France.

Susan Coles is a specialist in corporate law with over 25 years of experience in international collaborations and corporate/commercial activities, including more than 20 years in the life sciences sector. Susan is General Counsel and Head of Finance at Vivet Therapeutics, a private gene therapy biotech company with a strong investor base, including Roche Venture Fund, Novartis Venture Funds, HealthCap, Columbus Venture Partners, Kurma Partners, Ysios Capital, Idinvest Partners and Pfizer Inc.
Prior to joining Vivet Therapeutics, Susan was General Counsel for 3 years at Stallergenes, a global leader in allergy immunotherapy, and also acted as General Counsel for 4 years at Inventiva, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq.
Between 2002-2012, Susan was Senior Counsel in charge of Licensing and Acquisitions at Laboratoires Fournier and subsequently at Solvay Pharmaceuticals, after its acquisition of Laboratoires Fournier.
Prior to these experiences, Susan worked for over 7 years in the field of international partnerships and mergers and acquisitions. Susan has a strong track record in advising senior management on strategic and operational matters as well as broad experience in business negotiation and strategic transactions. She holds a B.A. in Psychology from the University of British Columbia, and an LLB from the University of Toronto. Susan is an attorney of the Bar of Ontario and the New York Bar.

Dr. Alexandra Glucksmann is a seasoned US biopharma executive and experienced scientist with over 30 years of managerial experience in biotech. She is currently President and CEO of Sensorium Therapeutics, a private CNS focused biotech company, and serves on the board of Directors of Regenxbio, a US NASDAQ listed pre-commercial biotech focused on gene therapy. Previously, she was President and CEO at Cedilla Therapeutics and an Entrepreneur-in-Residence at Venture Capital firm Third Rock Ventures where she focused on company formation. During her tenure at Cedilla, she successfully led the company from its launch through to Series B, securing significant funding of $138 million. Earlier in her career, Dr. Glucksmann was a founding employee and the Chief Operating Officer at Editas Medicine, where she helped raise a total of $280 million from launch to IPO. She was also a founding employee and Senior Vice President of Research and Business Operations at Cerulean Pharma. She began her career at Millennium Pharmaceuticals as a research scientist and held roles of increasing responsibility, culminating in the role of Vice President of platform technology groups, prior to transitioning into a senior position in strategic program management and operations. Dr. Glucksmann earned her Ph.D. with honors in Molecular Genetics and Cell Biology from the University of Chicago in 1989 and completed her postdoctoral fellowship at the Massachusetts Institute of Technology in 1993.

Dr. C. A. (Oscar) Izeboud is CEO of Scenic Biotech, a drug discovery and development company focused on genetic modifiers, based in the Netherlands. Before joining Scenic Biotech, Dr. Izeboud was Managing Director at NIBC Bank N.V. in Amsterdam, where he headed a life sciences and healthcare team and led corporate finance and capital markets activities with a focus on innovative companies. Prior to that, as Managing Director at Kempen & Co., a Dutch investment bank, he built the Life Sciences and Healthcare franchise and played a pivotal role in numerous international transactions in biotech, medtech, and the healthcare industry. Before his transition to the banking sector, Dr. Izeboud’s initial interest was in the biotech industry where he spent a number of years working for Crucell NV, Specs BV, and TNO Pharma.
Dr. Izeboud has been a nonexecutive member of the board of directors of Luciole Medical AG since 2019, and a member of the board of Nomad Bioscience GmbH since 2020. He holds a Ph.D. in immunopharmacology from the University of Utrecht in the Netherlands.

Dr. Lee Schalop has a unique combination of biotech development expertise and deep financial industry knowledge. He was co-founder of Oncoceutics, Inc. (Oncoceutics), a clinical-stage drug discovery and development company with a novel brain cancer drug, and as Chief Executive Officer led a transformative acquisition of the company by Chimerix in January 2021 for $78 million plus up to $360 million in contingent milestone payments and royalties of 15- 20% on sales. In addition, Dr. Schalop served as Oncoceutics’ Chief Operating Officer from 2016 to 2020 and as the Chief Business Officer from Oncoceutics’ founding in 2009 until 2016. Prior to co-founding Oncoceutics, Dr. Schalop attended the Albert Einstein College of Medicine, graduating with a doctor of medicine degree in 2008. Before attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities. From 1985 to 1993, he was an investment banker, and his fund-raising activities included more than 10 initial public offerings, the largest of which raised over $700 million. From 1993 to 2004, he served as a research analyst and authored more than 1,000 reports covering more than 50 different publicly traded companies, earning a reputation for groundbreaking research. Dr. Schalop serves as a Board Observer at Chimerix Inc. and sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences.